Alzamend Neuro Inc

Alzamend Neuro Inc an early clinicalstage biopharmaceutical company focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders The companys pipeline includes AL001 that is in Phase II clinical trial which delivers a therapeutic combination of lithium proline and salicylate for the treatment of Alzheimers bipolar disorder posttraumatic stress disorder major depressive disorder other neurodegenerative diseases and psychiatric disorders and AL002 that completed preclinical stage which uses a method using a mutantpeptide sensitized cell as a cellbased therapeutic vaccine to restore the ability of a patients immunological system to combat Alzheimers disease Alzamend Neuro Inc was incorporated in 2016 and is headquartered in Atlanta Georgia